Background {#Sec1}
==========

Acute coronary syndromes (ACS) in diabetic patients are associated with increased overall risk compared to the general ACS population despite unquestionable advances in treating these patients \[[@CR1]\]. Most patients are treated with percuatenous intervention (PCI) with stent implantation \[[@CR2]\] while a minority are referred for coronary artery bypass grafting (CABG). Still, recurrent ischemia is a common clinical phenomenon among patients with diabetes \[[@CR3]\]. For some time now newer antiplatelet agents, such as ticagrelor and prasugrel, have been preferentially advocated for use in ACS instead of clopidogrel. However, in many centers worldwide the routinely used antiplatelet agent in most settings is still clopidogrel \[[@CR4], [@CR5]\]. It is generally recognized that many patients exhibit diminished response to clopidogrel \[[@CR6]\]. This problem may be and probably is even more important in diabetic ACS patients than in the unselected patient population treated with PCI \[[@CR7], [@CR8]\]. The clinical relevance of inadequate reduction of platelet aggregation by antiplatelet agents has now been a matter of debate for some years \[[@CR9]--[@CR15]\]. Many observational studies show it to be of paramount importance, while some randomized trials are much less conclusive \[[@CR16]--[@CR19]\].

There are several methods of assessing platelet aggregation accepted for clinical use, such as Verify Now (Accriva Diagnostics, San Diego, CA, USA), Multiplate (Roche Diagnostics, Rotkreuz, Switzerland), VASP (Diagnostica Stago, Asnieres sur Seine, France) and some others, less standardized \[[@CR20]--[@CR22]\]. Based on available evidence from randomized trials none of these methods is currently recommended for routine clinical use as the efficacy of routine platelet function tests for guiding the treatment has not been confirmed \[[@CR23], [@CR24]\].

Most studies examining platelet aggregation, either ADP or aspirin induced, were done in cohorts of stable coronary artery disease (CAD) patients after elective PCI procedures or in unselected all-comer populations \[[@CR25], [@CR26]\]. There are less studies in patients with ACS and the data on diabetic patients is mostly derived from subgroup analyses of large all-comer studies \[[@CR27]--[@CR30]\].

Hence, the aim of the present study was to prospectively assess whether the degree of platelet aggregation inhibition in a high risk population of diabetic ACS patients on clopidogrel, treated with PCI, affects outcome. The clinical outcome endpoints were certain or probable stent thrombosis, and bleeding. The study also attempted to elucidate what is the best cutoff point of aggregations values for predicting stent thrombosis and bleeding in this population.

Methods {#Sec2}
=======

This was a prospective single-center observational study into which 206 diabetic patients admitted for ACS to the Institute of Cardiology in Warsaw were enrolled in the years 2011--2014.

Ethics, consent and permissions: The study protocol was approved by the local Ethical Review Board and conducted in accordance with the Declaration of Helsinki. The study was financed by a National Science Centre grant NN 402381438.

Consecutive diabetic patients admitted for ACS treated by successful PCI with stent implantation were included. ACS, either STEMI or NSTEMI in case of the analyzed group, was defined according to the Third Universal Definition of Myocardial Infarction \[[@CR31]\]. Patients on chronic anticoagulants or medications known to influence platelet aggregation (such as non-steroid anti-inflammatory agents or steroids) were excluded.

The primary endpoint of the study was definite or probable stent thrombosis as defined by the Academic Research Consortium criteria \[[@CR32]\] and major or moderate bleeding as assessed by the GUSTO \[[@CR33]\] study criteria.

The secondary endpoints of the study were cardiovascular and overall mortality \[[@CR34]\] within one year.

All patients were loaded with 600 mg of clopidogrel either prior to or immediately after admission and received 300 mg of aspirin. Angiography and PCI procedures were performed according to the guidelines of the European Society of Cardiology \[[@CR23]\], with no restriction as to stent selection, which was left to the discretion of the operator. Post-dilatation with non-compliant balloons for procedure optimization was strongly encouraged.

Platelet function assessment {#Sec3}
----------------------------

ADP-induced platelet reactivity assessment was performed directly prior to patient discharge, but no earlier than in the fourth day after admission. The MEA (multiple electrode platelet aggregometry) analyzer Multiplate (Dynabyte, Munich, Germany) was used. The method has been reapeatedly described previously \[[@CR35], [@CR36]\]. In short, 3 ml of whole blood is collected into a tube containing a direct thrombin inhibitor. After dilution with saline and agitation while incubating at 37 °C for 3 min in test cuvettes, 6.4 μmol ADP was added. Platelet aggregation was recorded continuously for 6 min and plotted against time in AU x min arbitrary units representing the area under the curve (ADPtest).

The same analyzer was also used to assess platelet response to acetylsalicylic acid (ASA). In this case 0.5 mM solution of arachidonic acid was used as agonist (ASPItest).

Study personnel was blinded to the results of the tests -- the test result database was accessed for analysis only after completing patient follow-up.

Clinical follow-up {#Sec4}
------------------

Clinical follow-up was done by outpatient visit or telephone interview with the patient at 30 days and 12 months after the PCI procedure. Data was entered into a computer database. In case of endpoint or adverse event occurrence every effort was made to obtain and review source documentation.

Statistics {#Sec5}
----------

Group (sample) size was calculated based on data from literature such as the risk of ischemic events and percentage of patients on clopidogrel showing reduced response to the drug. The Power and Sample Size Calculator software was used. We inferred that combined endpoint frequency will be 20% in patients with inadequate clopidogrel response and 8% in patients with adequate response. In order to achieve 80% power (beta 0.8) at the significance level of 0.05 we needed to include 192 patients. Data was collected on preprinted forms and entered into a database. Statistical analysis was performed using SPSS 22 (IBM Corp., USA) and SAS 9.2 (SAS Institute, Cary, NC, USA) software. Normally distributed variables were presented as means and standard deviation, while non-normally distribute variables as medians and interquartile range. Categorical variables were presented as percentages of patients exhibiting a given trait. Depending on distribution variables were analyzed using Student's *t*-test or Mann-Whitney *U*-test. Chi-square test was used for categorical variables. If the number of values was less than 5, Fisher's exact test was used. Correlation between linear variables was assessed with Pearson's test. The analysis of endpoints was performed using the Kaplan-Meier method (K-M). The censored observation model was employed. The curves were compared using the log rank test. In order to elucidate variables influencing outcome a Cox proportional hazard model was used with the forward conditional Wald variant. A ROC (receiver operator characteristic) curve analysis was calculated to determine optimal platelet aggregation cutoff values both for thrombotic episodes and for bleeding. A P value of less than 0.05 was considered statistically significant in all analyses.

Results {#Sec6}
=======

A total of 206 diabetic patients treated with PCI for ACS were enrolled in the trial, out of which 6 (2.9%) did not complete follow-up.

The ADP-induced platelet reactivity and the risk of definite or probable stent thrombosis {#Sec7}
-----------------------------------------------------------------------------------------

During one year follow-up there were 7 cases of definite stent thrombosis and 1 case of sudden cardiac death adjudicated as probable stent thrombosis. They occurred between day 3 and day 360 after the PCI procedure.

The patients were divided into two groups --- adequate response to clopidogrel and impaired response to clopidogrel based on the ADP-induced platelet aggregation MEA Multiplate test result. Two cutoff values of ADP-dependent platelet aggregation as assessed by MEA were analyzed.

The first cutoff point equaling 468 AU x min was accepted based on previous literature data and the consensus of the Working Group on On-Treatment Platelet Reactivity. This cutoff point had been elucidated after analyzing lower risk patient groups (mostly non-diabetic patients undergoing elective procedures) than in the case of this paper. This however is the generally accepted reference cutoff for the Multiplate test.

The second, calculated based on ROC curve analysis, was 345 AU x min. Despite this being the best fit, the statistical significance was not reached, possibly due to low endpoint frequency (ROC curve analysis: sensitivity 75%, specificity 82%, AUC under the ROC curve 0.72, 95% confidence interval 0.47--0.97, *P* = 0.08; Fig. [1](#Fig1){ref-type="fig"}). However, this cutoff related better to study endpoints in the analyzed cohort.Fig. 1ROC curve calculated for ADP-dependent platelet aggregation as assessed by MEA (ADPtest)

The clinical and demographic characteristics of the studied group are presented in Table [1](#Tab1){ref-type="table"}.Table 1Clinical and demographic data of the studied group with respect to platelet aggregation assessed by MEA Multiplate analyzer at the cutoff point of 345 AUminADPtestADPtest*P*-value\<345 AU × min345 ≥ AU × min*n* = 160*n* = 40Age (years) (mean ± SD)66.5 ± 11.169.6 ± 10.8*p* = 0.084Male (%)109 (68%)29 (72.5%)*p* = 0.593STEMI (%)74 (53%)20 (50%)*p* = 0.695ASPItest (AU x min)88.9 ± 73.0173.1 ± 150.0*p* \< 0.001Drug eluting stent132 (94%)33 (83%)*p* = 0.911Stent diameter (mm) (median)3.03.0*p* = 0.450Stent (s) length (mm)18.022.0*p* = 0.247Inflation pressure (atm) (median)16.016.0*p* = 0.809Fibrinogen (mg/dL) (mean ± SD)451 ± 133480 ± 138*p* = 0.358LDL (mmol/L) (mean ± SD)2.83 ± 1.12.58 ± 0.9*p* = 0.278Creatinine (umol/L) (mean ± SD)92.9 ± 34.4103.4 ± 67.6*p* = 0.421hsCRP (mg/dL) (median)0.40.5*p* = 0.396Platelet count (10^3^/ml) (mean ± SD)204 ± 60223 ± 70*p* = 0.117White blood count (10^3^/ml) (mean ± SD)8.658.45*p* = 0.793Hemoglobin (mg/dL) (median)13.812.8*p* = 0.067Insulin therapy46 (33%)15 (38%)*P* = 0.293

The degree of inhibition of arachidonic acid induced platelet aggregation (ASPItest) was the only difference between the two groups of patients --- above (impaired response) and below (adequate response) the 468 AU x min cutoff point. The ASPI test result difference remained statistically significant also when the standard 345 AU x min cutoff point was used.

Primary endpoint analysis at the ADPtest cutoff point of 468 AUmin {#Sec8}
------------------------------------------------------------------

In the case of the advocated reference platelet aggregation cutoff point of 468 AUmin, the risk of definite stent thrombosis was not significantly higher in the impaired clopidogrel response group (HR 4.21; 95% CI 0.82--21.68; *P* = 0.086) compared to the remaining group. However, the risk of definite or probable stent thrombosis was significantly higher in the impaired response group (HR 6.40; 95% CI 1.53--26.81; *P* = 0.011; Fig. [2a](#Fig2){ref-type="fig"}).Fig. 2**a** Hazard ratio values of stent thrombosis (as described in the Figure) plotted as HR with 95% confidence intervals for standard MEA cutoff value of 468 AUmin; Inset (**b**) Hazard ratio values of stent thrombosis and cardiovascular mortality (as described in the Figure) for the cutoff of 345 AUmin that allowed for better risk stratification in the studied cohort

Primary endpoint analysis at the ADPtest cutoff point of 345 AUmin {#Sec9}
------------------------------------------------------------------

When dividing patients into two groups at the cutoff point of 345 AU x min (based on ROC curve analysis), the risk of definite stent thrombosis proved to be significantly higher in the impaired clopidogrel response group (above 345 AU x min; HR 10.15; 95% CI 1.97--52.34; *P* = 0.006). Similarly, the risk of definite or probable stent thrombosis was significantly higher in the impaired response group (HR 12.33; 95% CI 2.49--61.1; *P* = 0.002; Fig. [2b](#Fig2){ref-type="fig"}).

Risk of stent thrombosis and other potential influencing factors {#Sec10}
----------------------------------------------------------------

In the Cox model analysis there was no increased risk of stent thrombosis related to the response to aspirin assessed by MEA, despite this parameter being different between groups irrespectively of the cutoff point (compare Table [1](#Tab1){ref-type="table"}). The only other factor related to the risk of definite or probable stent thrombosis was hsCRP serum concentration (HR 1.11; 95% CI 1.01--1.22; *P* = 0.03).

None of the other clinical or demographic factors out of those presented in Table [1](#Tab1){ref-type="table"} were related to the risk of stent thrombosis in the Cox model.

The analysis of secondary endpoints {#Sec11}
-----------------------------------

Cardiovascular death within one year occurred in 7 patients. The risk of cardiovascular death was significantly higher for patients with ADPtest values above 345 AU x min compared to the remaining group (Cox regression, HR 10.58; 95% CI 2.05--54.58; *P* = 0.005), but not in case of the cutoff point of 468 AU x min (*P* = 0.076). Furthermore, the risk of cardiovascular mortality was also higher when the ADPtest was used as a linear variable (HR 1.002; 95% CI 1.0001--1.005; *P* = 0.04).

Overall, 11 patients died during the one-year follow-up. The risk of any-cause death was significantly higher only in case of patients with ADPtest values above 345 AU x min (HR 3.48; 95% CI 1.06--11.39; *P* = 0.04) compared to the remaining group.

Bleeding {#Sec12}
--------

Major bleeding as defined by GUSTO II criteria occurred in 5 patients, while major or moderate bleeding in 24 patients. Based on ROC curve analysis for ADP-induced platelet aggregation and major or moderate bleeding, the best cutoff point discriminating the population at risk for bleeding was calculated. The MEA aggregation value of 278 AUmin proved the best cutoff point for bleeding in this population (sensitivity 88%, specificity 42%; ROC curve AUC 0.61, 95% CI 0.51--0.72; *P* = 0.034). However, in the Cox proportional hazards model neither the cutoff point of 278 AU x min nor the cutoff point used for unselected groups in earlier literature (188 AU x min) was significantly related to increased bleeding risk.

Discussion {#Sec13}
==========

In this prospective observational study we analyzed the risk of stent thrombosis and bleeding in diabetic patients presenting with an acute coronary syndrome and pretreated with clopidogrel and aspirin before PCI. The relative risk was assessed in relation to the extent of ADP-induced platelet aggregation measured by MEA Multiplate analyzer.

We found that increased platelet reactivity (or inadequate platelet inhibition) in patients on clopidogrel is related to increased risk of stent thrombosis and cardiovascular mortality within one year. In the studied cohort, the optimal discriminating cutoff point of platelet reactivity above which the risk of stent thrombosis is higher was found to be 345 AU x min. The optimal cutoff point for the risk of bleeding was, in turn, 278 AU x min.

To date, the clinical implications of platelet reactivity in patients after PCI were assessed in numerous studies using a number of different methods, also the MEA Multiplate analyzer \[[@CR37]--[@CR39]\]. Most of the studied patient cohorts consisted of elective low stent thrombosis risk patients or unselected all-comer PCI patients \[[@CR40]--[@CR42]\]. These and other prior studies suggest that the risk of stent thrombosis is highest in acute coronary syndrome patients, while diabetes is an additional important concomitant condition increasing this risk \[[@CR43]--[@CR50]\].

Observational studies in elective patients, consecutive patient cohorts and the several ACS patient groups, with few exceptions, quite uniformly showed an increased risk of stent thrombosis in patients with inadequate inhibition of platelet aggregation \[[@CR51]--[@CR56]\]. Different methods of laboratory assessment of platelet aggregation were used with the MEA Multiplate method repeatedly showing consistent results across several studies \[[@CR20], [@CR35], [@CR57]\].

This evidence spurred randomized trials that have to date failed to confirm the relationship of platelet aggregation values assessed by laboratory methods and stent thrombosis. The results of several such trials have been published. One of them was a subgroup study within the TRILOGY-ACS trial \[[@CR58]\], where conservatively treated patients had platelet reactivity assessed with the VerifyNow assay. No difference was found between patients treated with clopidogrel or more aggressively -- with prasugrel. In other studies, such as the GRAVITAS, ARCTIC and TRIGGER-PCI \[[@CR16], [@CR59]--[@CR62]\], platelet reactivity was assessed using different methods in patients after PCI procedures, on different treatment regimens, but the extent of platelet inhibition did not translate into a difference in the risk of stent thrombosis or ischemic events. Two trials, a non-randomized MADONNA study \[[@CR63]\] and the small randomized study by Hazarbasanova et al. \[[@CR29]\] showed that modifying therapy based on platelet aggregation assessment using the Multiplate analyzer might bear on outcome.

The present study was undertaken as we felt there was lack of direct specific data concerning platelet reactivity and outcome in high risk populations and because of conflicting evidence of the above-mentioned studies.

Despite enrolling a comparatively small cohort and relatively few occurrences of primary endpoint we have shown that increased platelet reactivity in clopidogrel treated diabetic ACS patients after PCI is related to increased risk of stent thrombosis. The optimal cutoff point, above which platelet reactivity may be considered overt and related to stent thrombosis in the studied cohort was 345 AU x min, less than the generally accepted cutoff elucidated in earlier studies. However, also the standard cutoff of 468 AU x min allowed to discriminate the group of patients at increased risk for stent thrombosis. It must be noted that this lower cutoff, although providing better risk stratification did not reach significance in ROC curve analysis. The difference between the optimal cutoff between this and earlier studies must therefore be considered an approximation and is most probably the effect of different cohorts studied. In most trials to date the majority of enrolled patients were low risk patients. In this study of diabetic patients presenting with ACS the extent of platelet inhibition in order to avoid stent thrombosis may be expected to be higher \[comp. [@CR30]\]. The study also showed that patients with higher ADP-induced platelet reactivity on clopidogrel also show diminished response to aspirin \[comp. [@CR26]\]. We have not, however, seen an increase in the risk of stent thrombosis in relation to arachidonic acid induced platelet reactivity alone.

Decreased platelet aggregation invariably results in an increase of bleeding risk as has been repeatedly reported in previous studies \[[@CR35], [@CR64], [@CR65]\]. In the analyzed cohort one may reasonably expect both increased stent thrombosis and increased bleeding risk compared to unselected populations. This was confirmed by finding that the optimal cutoff point for increased bleeding in the studied group was 278 AU x min -- higher than the "standard" cutoff for bleeding of 188 AU x min elucidated in previous studies. However, we did not find a clear relation of this cutoff to the risk of bleeding.

Based on the data acquired in the study one may think that the therapeutic window for clopidogrel assessed with the MEA Multiplate analyzer is more narrow for our study group than for an unselected lower risk cohort of patients after PCI. Newer antiplatelet drugs, such as prasugrel and ticagrelor act more uniformly than clopidogrel and provide greater inhibition of platelet aggregation. Therefore, as clinical data from other studies show \[[@CR41], [@CR44]\], in a high risk population such as the one analyzed, they provide better protection against stent thrombosis at the cost of greater bleeding risk. Platelet function monitoring using, for example, the MEA Multiplate method in high risk cohorts, could lead to a reduction in bleeding without unduly increasing the risk of stent thrombosis. Such monitored therapy need not be confined just to one antiplatelet drug and should allow for modifying therapy if necessary \[[@CR66]\]. This approach requires confirmation in randomized trials, especially since there may be several seemingly attractive strategies of monitored antiplatelet therapy.

Study limitations {#Sec14}
-----------------

The major inherent limitation of this study is its observational character, not allowing for causal analysis. The study cohort is relatively small. The primary study endpoint occurred in only 8 patients which precluded meaningful multifactorial analysis. On the other hand, apart from ADP-induced platelet aggregation, practically no other analyzed factors correlated with increased risk of stent thrombosis upon single factor analysis, so it may be considered an independent association. Platelet reactivity was measured only once in every patient, but at a period where drug effect should be full. However, the absence of repeated measurements would fail to identify patients who stopped taking the drug despite recommendations. Patients in this study were treated with clopidogrel, which at the time of study commencement was the only routinely used antiplatelet drug in our country. At present, newer antiplatelet agents are preferentially recommended that inhibit platelet aggregation more profoundly, but their use is still not dominant in most areas. It is difficult to predict how they would influence study outcomes as far as stent thrombosis and bleeding are concerned.

Conclusions {#Sec15}
===========

This work shows that in a high risk population of patients with ACS and diabetes treated with stent implantation and receiving clopidogrel, higher on-treatment platelet reactivity is related to increased risk of stent thrombosis at 1-year follow-up. Whether platelet reactivity-guided therapy may decrease the risk of stent thrombosis and patient prognosis must be resolved in randomized trials, a few of which are already underway.
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:   Acute coronary syndrome

ADP

:   Adenosine-diphosphate

ADPtest

:   Multiplate analyzer test for assessing platelet aggregation on clopidogrel

ASA

:   Acetylsalicylic acid

ASPItest

:   Multiplate analyzer test for assessing platelet aggregation on aspirin

AU x min

:   Arbitrary units used for expressing aggregation values measured with the Multiplate analyzer

10 AU x min is equivalent to 1 U

:   Another arbitrary unit also used for the same purpose

CABG

:   Coronary artery bypass grafting

CAD

:   Coronary artery disease

ECG

:   Electrocardiogram

GUSTO

:   Global utilization of streptokinase and TPA for occluded arteries trial

hsCRP

:   High sensitivity C-reactive protein

MEA

:   Multiple electrode platelet aggregometry

NSTEMI

:   Non-ST elevation myocardial infarction

PCI

:   Percutaneous coronary intervention

ROC

:   Receiver operator characteristic

STEMI

:   ST elevation myocardial infarction
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